AllianceBernstein Holding LP is a publicly owned investment manager. The company is headquartered in New York, New York.
| Revenue (TTM) | $332.76M |
| Gross Profit (TTM) | $332.76M |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 19.10% |
| Return on Assets | -3.90% |
| Revenue/Share (TTM) | $3.29 |
| Book Value | $13.50 |
| Price-to-Book | 2.81 |
| Price-to-Sales (TTM) | 10.69 |
| EV/Revenue | 10.34 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 37.70% |
| Quarterly Revenue Growth (YoY) | -40.30% |
| Shares Outstanding | $93.40M |
| Float | $92.64M |
| % Insiders | 2.05% |
| % Institutions | 13.16% |
Volatility is currently contracting
AllianceBernstein NYSE: AB reported record assets under management and its strongest quarterly sales in five years during the second quarter of 2026, as fixed-income demand, private-market deployments and insurance-related mandates helped the firm return to positive organic growth.
GAAP Net Income of $0.77 per Unit Adjusted Net Income of $0.82 per Unit Cash Distribution of $0.82 per Unit NASHVILLE, Tenn., July 28, 2026 /PRNewswire/ -- AllianceBernstein L.P.
NASHVILLE, Tenn., July 13, 2026 /PRNewswire/ -- AllianceBernstein L.P.
NASHVILLE, Tenn., July 6, 2026 /PRNewswire/ -- AllianceBernstein L.P.
AB Akola Group, ISIN code LT0000128092, (hereinafter - the Company), has received a notification from the person discharging managerial responsibilities regarding the transactions in the Company's securities (enclosed).
PRESS RELEASE AB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE RESISTANT PROSTATE CANCER FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION UNTIL 2042 THIS POSITIVE DECISION FROM THE USA PATENT OFFICE ADDS TO THE COVERAGE ALREADY GRANTED IN EUROPE Paris, June 17, 2026, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the United States Patent Office has formally granted a patent for methods of treating metastatic castrate resistant prostate cancer (mCRPC) with its lead compound masitinib. This new US patent (US 12,648,944) ensures intellectual property protection for masitinib until May 2042.
AllianceBernstein offers a compelling value proposition, trading at 11x earnings with a ~9% yield in an expensive market. AB's diversified business model, global footprint, and no-debt balance sheet provide stability and multiple fee streams across institutional, retail, and private wealth channels. The distribution is variable but well-covered by operating cash flow, offering tax advantages and a steady income profile for patient, long-term investors.
NASHVILLE, Tenn., June 10, 2026 /PRNewswire/ -- AllianceBernstein L.P.
BKR, ASH and AB have been added to the Zacks Rank #5 (Strong Sell) List on May 28, 2026.
AB, BFC and ERIE have been added to the Zacks Rank #5 (Strong Sell) List on May 21, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AB and any ticker you trade — then tracks every position and per-strategy win rate.
